Valirx (VAL) RNS Announcements

Add to Alert list
Date Time Source Announcement
21 Mar 2024 07:00 AM
RNS
Evaluation Agreement with Imperial College London
19 Mar 2024 07:00 AM
RNS
Board Re-structuring and update on requisition
04 Mar 2024 05:47 PM
RNS
Shareholder Requisition Notice
04 Mar 2024 07:00 AM
RNS
Proposed Appointment of Non-Executive Director
29 Feb 2024 02:00 PM
RNS
Proposed Appointment of Non-Executive Director
13 Feb 2024 02:20 PM
RNS
Further re Shareholder Requisition Notice
12 Feb 2024 05:33 PM
RNS
Holding(s) in Company
12 Feb 2024 07:00 AM
RNS
Agreement with Dundee Uni and Project Initiation
09 Feb 2024 05:06 PM
RNS
Shareholder Requisition Notice
19 Jan 2024 07:00 AM
RNS
Change of Broker
18 Jan 2024 07:00 AM
RNS
Directorate Change
04 Jan 2024 01:48 PM
RNS
Result of GM, Issue of Equity
19 Dec 2023 06:11 PM
RNS
Result of Retail Offer, Subscription
15 Dec 2023 07:00 AM
RNS
Posting of Circular, Notice of GM and Ops Review
13 Dec 2023 04:56 PM
RNS
Retail Offer
13 Dec 2023 04:49 PM
RNS
Conditional Fundraise, Notice of General Meeting
05 Dec 2023 07:00 AM
RNS
Agreement to License VAL401 to Ambrose Healthcare
10 Nov 2023 07:00 AM
RNS
Evaluation Agreement with StingRay Bio
06 Oct 2023 10:45 AM
RNS
Statement re Share Price Movement
28 Sep 2023 07:00 AM
RNS
Operational Review
24 Aug 2023 07:00 AM
RNS
Half-year Report
14 Aug 2023 07:00 AM
RNS
Collaborative Services Agreement
19 Jul 2023 07:00 AM
RNS
Inaphaea BioLabs secures first external contract
28 Jun 2023 02:15 PM
RNS
Result of AGM
20 Jun 2023 07:00 AM
RNS
Virtual AGM Access
19 Jun 2023 07:00 AM
RNS
Inaphaea BioLabs Operational Update
16 Jun 2023 07:00 AM
RNS
Conclusion of Hokkaido Evaluation Agreement
14 Jun 2023 07:00 AM
RNS
Asset Purchase – Imagen Therapeutics
08 Jun 2023 07:00 AM
RNS
Update on proposed sub-license of VAL201
07 Jun 2023 07:00 AM
RNS
Expanded agreement with University of Barcelona
05 Jun 2023 07:00 AM
RNS
Final Results and Notice of AGM
26 May 2023 07:00 AM
RNS
Notice of Results and Investor Webinar
02 May 2023 02:29 AM
BZW
Valaris Announces Appointment of New ARO Dril...
02 May 2023 02:28 AM
BZW
Valaris Provides Fleet Status Report
02 May 2023 02:12 AM
BZW
Valaris Reports First Quarter 2023 Results
26 Apr 2023 07:00 AM
RNS
Collaborative Services Agreement
31 Mar 2023 07:00 AM
RNS
Quarterly Operational Update
01 Mar 2023 07:02 AM
RNS
Investor Webinar
01 Mar 2023 07:00 AM
RNS
Incorporation of Inaphaea BioLabs Limited
24 Feb 2023 04:40 PM
RNS
Second Price Monitoring Extn
24 Feb 2023 04:35 PM
RNS
Price Monitoring Extension
02 Feb 2023 12:45 PM
RNS
Result of GM, Issue of Equity
31 Jan 2023 07:02 AM
RNS
Operational Update
31 Jan 2023 07:00 AM
RNS
Holding(s) in Company
17 Jan 2023 04:36 PM
RNS
Broker Offer Results
17 Jan 2023 09:22 AM
RNS
Posting of Circular and Notice of General Meeting
13 Jan 2023 07:01 AM
RNS
Launch of Broker Offer
13 Jan 2023 07:00 AM
RNS
Issue of Equity & Proposed Broker Offer
14 Dec 2022 05:01 PM
RNS
Holding(s) in Company
07 Dec 2022 01:06 PM
RNS
Holding(s) in Company

ValiRx PLC: A Biotech Innovator on the London Stock Exchange (LSE)

ValiRx PLC, known by its ticker symbol VAL, is a trailblazer in the biotechnology sector. Its performance on the London Stock Exchange (LSE) has been remarkable, with the ValiRx share price reflecting the company's consistent growth and success.

As a member of the LSE, ValiRx PLC aligns with the London Stock Exchange Group's (LSEG) mission of supporting innovative and growing businesses. The LSEG recognises ValiRx PLC as a significant player, contributing to the robust and diverse ecosystem of the LSE.

The ValiRx share price on the LSE not only underscores its financial stability but also its strategic vision in the biotechnology industry. ValiRx PLC's journey on the LSE is a testament to its robust business model and its ability to create value for its stakeholders.

In conclusion, ValiRx PLC's association with the LSE and LSEG symbolises its commitment to growth, innovation, and value creation. As ValiRx PLC continues to thrive on the LSE, it sets the bar high for the biotechnology industry, contributing to the dynamic and diverse ecosystem of the LSEG. With its focus on cancer therapeutics, ValiRx is a key player in the healthcare sector, making strides in medical research and development.

UK 100